US-listed shares of Novo Nordisk jumped 4% in premarket trading. The Wegovy maker on Wednesday forecast sales would grow at a slower rate this year although the outlook was roughly in line with market expectations as the pace of ferocious demand for its wildly popular obesity drug Wegovy eases somewhat.

The Danish company said it expects sales growth in local currencies to range between 16% and 24%, less than the 26% growth seen in 2024. That compares with analysts expectations of just under 20%.

It said fourth-quarter operating profit jumped 37% to 36.7 billion Danish crowns ($5.12 billion), better than the 33.6 billion forecast by analysts in a company poll.

During the fourth quarter, sales of Wegovy more than doubled to 19.9 billion crowns from 9.6 billion a year ago, in line with expectations and more than the 17.3 billion crowns achieved in the third quarter.

GSK stock rose over 5% after posting a better-than-expected fourth quarter on Wednesday and lifted its 2031 sales target to nearly $50 billion as the British drugmaker aims to invest heavily in its specialty medicines to offset weakness in vaccine.

GSK's fourth-quarter earnings topped estimates as strength in its HIV and oncology portfolio offset a fall in sales of its respiratory syncytial virus (RSV) and shingles shots.

"We are increasing and prioritising R&D investment to promising new long-acting and specialty medicines in Respiratory, Immunology & Inflammation, Oncology and HIV," CEO Emma Walmsley said in a statement.

Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit hurdles in the United States, including changes in public health agency recommendations, prioritisation of other vaccinations such as COVID-19 and lower seasonal infections.

US-listed shares of Toyota jumped 2.88% in premarket trading. Japan's Toyota Motor raised its full-year operating profit forecast by 9% on Wednesday, in a sign of confidence in its ability to ride out the impact of any potential U.S. tariffs.

The world's top-selling automaker raised its profit forecast for the current year through March 2025 to 4.7 trillion yen ($30.7 billion) versus 4.3 trillion yen expected previously.

The revision reflected efforts to strengthen its earnings power through keeping a lid on incentives, raising prices and stabilising production, Toyota said in presentation materials. It also expects to gain from a weak yen.

Snap Inc beat Wall Street estimates for quarterly profit on Tuesday, benefiting from improvements to the Snapchat parent's advertising platform, sending its shares up 4.8% in premarket trading.

Snap could increase price of its Snapchat+ subscription service to boost average revenue per user, Spiegel added. In the fourth quarter, Snapchat+ subscribers doubled to 14 million.

Enphase Energy guided for better-than-expected sales in the current quarter, boosting the stock of the microinverter maker by 8% in premarket trading.